Compare GTLS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTLS | PRAX |
|---|---|---|
| Founded | 1859 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 9.6B |
| IPO Year | N/A | 2020 |
| Metric | GTLS | PRAX |
|---|---|---|
| Price | $206.61 | $321.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 15 |
| Target Price | $203.22 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 2.1M | 339.2K |
| Earning Date | 04-30-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.24 | N/A |
| Revenue Next Year | $6.26 | $6,395.88 |
| P/E Ratio | $240.25 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $104.60 | $26.70 |
| 52 Week High | $208.24 | $354.87 |
| Indicator | GTLS | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 42.96 | 55.62 |
| Support Level | $206.55 | $284.60 |
| Resistance Level | $207.59 | $322.32 |
| Average True Range (ATR) | 0.48 | 18.17 |
| MACD | -0.05 | 0.40 |
| Stochastic Oscillator | 24.40 | 97.68 |
Chart Industries provides a variety of cryogenic equipment for storage, distribution, and other processes within the industrial gas and liquefied natural gas industries. It also provides natural gas processing solutions for the natural gas industry and specialty products that serve a variety of spaces, including hydrogen, biofuels, cannabis, and water treatment. The firm acquired Howden in a significant deal in early 2023, roughly doubling the size of the company. It plans to merge with Flowserve by the end of 2025.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.